Literature DB >> 10519895

Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment.

A van Rie1, R Warren, M Richardson, T C Victor, R P Gie, D A Enarson, N Beyers, P D van Helden.   

Abstract

BACKGROUND: For decades it has been assumed that postprimary tuberculosis is usually caused by reactivation of endogenous infection rather than by a new, exogenous infection.
METHODS: We performed DNA fingerprinting with restriction-fragment-length polymorphism analysis on pairs of isolates of Mycobacterium tuberculosis from 16 compliant patients who had a relapse of pulmonary tuberculosis after curative treatment of postprimary tuberculosis. The patients lived in areas of South Africa where tuberculosis is endemic. Medical records were reviewed for clinical data.
RESULTS: For 12 of the 16 patients, the restriction-fragment-length polymorphism banding patterns for the isolates obtained after the relapse were different from those for the isolates from the initial tuberculous disease. This finding indicates that reinfection was the cause of the recurrence of tuberculosis after curative treatment. Two patients had reinfections with a multidrug-resistant strain. All 15 patients who were tested for the human immunodeficiency virus were seronegative.
CONCLUSIONS: Exogenous reinfection appears to be a major cause of postprimary tuberculosis after a previous cure in an area with a high incidence of this disease. This finding emphasizes the importance of achieving cures and of preventing anyone with infectious tuberculosis from exposing others to the disease.

Entities:  

Mesh:

Year:  1999        PMID: 10519895     DOI: 10.1056/NEJM199910143411602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  177 in total

1.  Analysis for a limited number of gene codons can predict drug resistance of Mycobacterium tuberculosis in a high-incidence community.

Authors:  A Van Rie ; R Warren; I Mshanga; A M Jordaan; G D van der Spuy ; M Richardson; J Simpson; R P Gie; D A Enarson; N Beyers; P D van Helden ; T C Victor
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

Review 2.  How molecular epidemiology has changed what we know about tuberculosis.

Authors:  M Kato-Maeda; P M Small
Journal:  West J Med       Date:  2000-04

3.  Molecular and conventional epidemiology of Mycobacterium tuberculosis in Botswana: a population-based prospective study of 301 pulmonary tuberculosis patients.

Authors:  S Lockman; J D Sheppard; C R Braden; M J Mwasekaga; C L Woodley; T A Kenyon; N J Binkin; M Steinman; F Montsho; M Kesupile-Reed; C Hirschfeldt; M Notha; T Moeti; J W Tappero
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

4.  The stringent response of Mycobacterium tuberculosis is required for long-term survival.

Authors:  T P Primm; S J Andersen; V Mizrahi; D Avarbock; H Rubin; C E Barry
Journal:  J Bacteriol       Date:  2000-09       Impact factor: 3.490

5.  Immunological and pathological comparative analysis between experimental latent tuberculous infection and progressive pulmonary tuberculosis.

Authors:  A K Arriaga; E H Orozco; L D Aguilar; G A W Rook; R Hernández Pando
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

6.  Can you get tuberculosis twice?

Authors:  John Hoey
Journal:  CMAJ       Date:  2002-02-19       Impact factor: 8.262

Review 7.  The many faces of host responses to tuberculosis.

Authors:  H L Collins; S H Kaufmann
Journal:  Immunology       Date:  2001-05       Impact factor: 7.397

8.  Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration.

Authors:  J L Johnson; A Okwera; P Nsubuga; J G Nakibali; C C Whalen; D Hom; M D Cave; Z H Yang; R D Mugerwa; J J Ellner
Journal:  Int J Tuberc Lung Dis       Date:  2000-11       Impact factor: 2.373

Review 9.  Mixed-strain mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control.

Authors:  Ted Cohen; Paul D van Helden; Douglas Wilson; Caroline Colijn; Megan M McLaughlin; Ibrahim Abubakar; Robin M Warren
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 10.  [Immunology of tuberculosis: impact on the development of novel vaccines].

Authors:  T Ulrichs; S H E Kaufmann
Journal:  Internist (Berl)       Date:  2003-11       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.